Search
Retinal-Health-DR-infographic
Public-Health-Cost-from-AF
What we do
Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Sustainable Development - Our Commitment
Our Commitment
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
Who are we?
Started in 1885 by Albert Boehringer, this independent family-owned company has grown into a top contributor in Human Pharma and Animal Health.
Global Careers Page
Join a global team of more than 52,000 passionate and talented individuals dedicated to improving the health of humans and animals worldwide.
Ryan Henri Rickards
Ryan Henry Rickards, a senior finance manager for US Animal Health Commercial Controlling team, highlights his career at Boehringer Ingelheim.
Andreas Lenk
Andreas Lenk, Head of Legal and Compliance Germany, discusses his role supporting human pharma and animal health business in legal and compliance matters.
Boehringer Ingelheim increases commitments to sustainable development
Boehringer Ingelheim increases commitments to sustainable development
Ontario
Boehringer Ingelheim Canada collaborates with premier institutions in Ontario to drive innovative solutions for high-quality healthcare. Click to read more.
Alberta
Learn about Boehringer Ingelheim Canada's strategic partnerships with leading institutions in Alberta to advance quality healthcare.
Quebec
Boehringer Ingelheim Canada joins forces with top institutions in Quebec to foster excellence in healthcare. Find out more about our partnering activities.
Western Canada
Boehringer Ingelheim Canada works hand in hand with prominent institutions in Western Canada. Find out more about our partnerships and their initiatives.
More Green
More Green
Thank you for submitting your report
multistep form
Retinal Diseases
Retinal Diseases
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF study
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF™ study
Sustainable Development
Sustainable Development
Heart Diseases
Heart Diseases
Science Stories
Science and Innovation - Human Health Innovation - Science Stories
Grass Roots
Science and Innovation - Human Health Innovation - Grass Roots
ABIC-COPD
Discover the ABIC Fund, developed to advance health innovation projects in the area of respiratory diseases, like COPD, for Alberta-based investigators.
Machine learning for patients
Using AI to power patient-centric guideline optimization: discover the collaboration between Boehringer Ingelheim Canada, a community of cardiologists and Ensho Health.